Aptevo Therapeutics Inc. (NASDAQ:APVO) Short Interest Down 57.0% in September

Aptevo Therapeutics Inc. (NASDAQ:APVO) was the target of a significant decrease in short interest during the month of September. As of September 15th, there was short interest totaling 43,900 shares, a decrease of 57.0% from the August 31st total of 102,200 shares. Based on an average trading volume of 4,120,000 shares, the days-to-cover ratio is presently 0.0 days. Currently, 1.5% of the company’s stock are sold short. Currently, 1.5% of the company’s stock are sold short. Based on an average trading volume of 4,120,000 shares, the days-to-cover ratio is presently 0.0 days.

Aptevo Therapeutics Price Performance

Aptevo Therapeutics stock opened at $1.43 on Friday. Aptevo Therapeutics has a one year low of $1.32 and a one year high of $381.10. The company’s fifty day moving average price is $1.88 and its two-hundred day moving average price is $7.86.

Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($8.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($83.20) by $74.80. Sell-side analysts anticipate that Aptevo Therapeutics will post -15.84 EPS for the current year.

Analyst Ratings Changes

APVO has been the topic of a number of research reports. Roth Capital raised shares of Aptevo Therapeutics to a “strong-buy” rating in a research note on Tuesday, September 16th. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Aptevo Therapeutics in a research note on Saturday, September 27th. Wall Street Zen raised shares of Aptevo Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 16th. Finally, Zacks Research raised shares of Aptevo Therapeutics to a “hold” rating in a research report on Thursday, September 18th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Aptevo Therapeutics has a consensus rating of “Hold”.

Institutional Investors Weigh In On Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Birchview Capital LP purchased a new stake in shares of Aptevo Therapeutics Inc. (NASDAQ:APVO) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,000 shares of the biotechnology company’s stock, valued at approximately $30,000. Birchview Capital LP owned 1.32% of Aptevo Therapeutics at the end of the most recent reporting period. 8.06% of the stock is owned by institutional investors and hedge funds.

Aptevo Therapeutics Company Profile

Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.